MainboardGMP
LIVE
LIVE GMP
Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·
Home › IPOs › Integris Medtech › Key Ratios
IN
Integris Medtech
UPCOMING NSE & BSE Bookbuilding IPO Fresh capital cum OFS Integris Medtech IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
—
Issue Price: ₹ 0
Issue Price
₹0
Face Value
₹1
Lot Size
0 shares
IPO Size
Agg. upto ₹600 Cr
Open Date
27 Nov 2026
Close Date
01 Dec 2026
Allotment
02 Dec 2026
Listing Date
04 Dec 2026
Exchange
NSE & BSE

Integris Medtech IPO Details: Price, Dates & Financials

The Integris Medtech IPO key financial ratios show a Return on Capital Employed (ROCE) of 14.51%. The Integris Medtech IPO Return on Equity (ROE) is 5.35%. The Integris Medtech IPO reports a Return on Net Worth (RONW) of 1.48%. For profitability analysis, the Integris Medtech IPO reports a Profit After Tax (PAT) margin of 3.72%. The Integris Medtech IPO EBITDA margin is 16.26%. Compare these Integris Medtech IPO key ratios with listed peers and read the offer document before taking a decision.

Integris Medtech IPO Key Financial Ratios
ROE
5%
ROCE
15%
RONW
1%
PAT Margin
4%
EBITDA Margin
16%
Integris Medtech IPO Key Ratios FAQs
As per the offer document, Integris Medtech has ROE 5.35%, ROCE 14.51%, RONW 1.48%.
Integris Medtech reports PAT margin 3.72% and EBITDA margin 16.26%.
ROE (return on equity) shows profit earned on shareholders' money, ROCE (return on capital employed) shows profit earned on all capital used in the business, and RONW (return on net worth) measures return on the company's net worth. Higher figures usually indicate more efficient use of capital.
Compare ROE, ROCE, margins and P/BV of Integris Medtech with listed companies in the same sector, and check the peer comparison given in the offer document. Ratios are only one input — they do not predict listing gains.
We require these key ratios to evaluate the financial health, profitability, valuation, and overall performance of the Integris Medtech IPO. They help investors understand how efficiently the company operates, how much debt it carries, and whether its shares are reasonably valued compared with its earnings and assets for that specific Integris Medtech IPO. These ratios also help assess the Integris Medtech IPOs ability to generate profits, manage financial obligations, and deliver sustainable growth, enabling investors to make a more informed Integris Medtech IPO investment decision.
Investors should examine the Integris Medtech IPO's revenue growth, profitability, debt levels, cash flow, and earnings per share (EPS). These indicators help assess the Integris Medtech IPO's financial stability, growth potential, and investment risks before investing in the Integris Medtech IPO.

GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.